2019
DOI: 10.1097/mpa.0000000000001368
|View full text |Cite
|
Sign up to set email alerts
|

Prevention of Infectious Complications in Acute Pancreatitis

Abstract: Objectives This study aimed to investigate the efficiency of imipenem to prevent infectious complications in predicted severe acute pancreatitis (AP). Methods Consecutive AP patients were randomized to imipenem 3 × 500 mg intravenously daily or an identical placebo. Exclusion criteria were prior AP, chronic pancreatitis, active malignancy, immune deficiency, active infection, concomitant antibiotic treatment, pregnancy, and patients younger than 18 year… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(3 citation statements)
references
References 13 publications
0
2
0
Order By: Relevance
“…The start of big randomized, double-blind, placebo-controlled trials on the other hand, i.e., Refs. [13][14][15][16][17], has not confirmed the previously recognized benefit of antibiotic therapy. Renewed evidence from randomized clinical trials (RCTs) has been confirmed by recent systematic reviews [18][19][20][21][22], and antimicrobials are currently recommended only when infection is either proven or strongly suspected [23].…”
Section: Introductionmentioning
confidence: 82%
“…The start of big randomized, double-blind, placebo-controlled trials on the other hand, i.e., Refs. [13][14][15][16][17], has not confirmed the previously recognized benefit of antibiotic therapy. Renewed evidence from randomized clinical trials (RCTs) has been confirmed by recent systematic reviews [18][19][20][21][22], and antimicrobials are currently recommended only when infection is either proven or strongly suspected [23].…”
Section: Introductionmentioning
confidence: 82%
“…However, despite the advantages of carbapenems' pharmacokinetic/pharmacodynamic (pk/pd) in pancreatic tissue, the effect of their prophylactic use on necrotic tissue infection and pancreatitis-related outcomes, such as mortality, is still uncertain. Particularly, high-quality randomized controlled trials with a low risk of bias have detected no relationship between prophylactic carbapenem use and pancreatitis-related outcomes ( 7 , 8 ). However, some observational studies have detected a reduction in infection risk through the use of prophylactic carbapenems, leading them to be used frequently in daily practice ( 9 ).…”
Section: Introductionmentioning
confidence: 99%
“…Infectious complications are a significant concern in the management of AP, as the control of infection can have a significant impact on patient outcomes [ 7 10 ]. To ensure the best possible outcome for patients, it is crucial to make an early and accurate diagnosis of infectious pancreatic necrosis.…”
Section: Introductionmentioning
confidence: 99%